1 2	State of Arkansas 89th General Assembly	A Bill	
3	Regular Session, 2013		SENATE BILL 965
4	C ·		
5	By: Senator J. Dismang		
6			
7	For An Act To Be Entitled		
8	AN ACT	N ACT TO AMEND UNCODIFIED SECTION 1 OF ACT 274 OF	
9	2013 TO	2013 TO EXCLUDE CERTAIN DRUGS FROM THE DEFINITION OF	
10	THERAPE	UTIC CLASS; AND FOR OTHER PURPOSES.	
11			
12			
13		Subtitle	
14	TO	AMEND UNCODIFIED SECTION 1 OF ACT 274	
15	OF 2013 TO EXCLUDE CERTAIN DRUGS FROM THE		
16	DE	FINITION OF THERAPEUTIC CLASS.	
17			
18			
19	BE IT ENACTED BY TH	E GENERAL ASSEMBLY OF THE STATE OF ARKANS	AS:
20			
21		ncodified Section 1 of Act 274 of 2013 is	amended to read
22	as follows:		
23		kansas Code § 17-92-101(17), concerning t	
24		e pharmacy act, is amended to read as fol	
25		"Prescription" means an order for medic	
26	-	a formula by a physician, optometrist, de	
27 28	-	her licensed medicinal practitioner. It s of the desired substance, with instruct	
20 29	-	preparation and to the patient for the us	
29 30	-	e and may authorize the pharmacist to sub	
31	-	ivalent drug that is at a lower cost to t	
32	communicate that authorization by any generally accepted means of		
33	communication of a prescription from a prescriber to a pharmacist.		
34	(B) A substitution of a therapeutically equivalent drug		
35	shall occur only after the prescriber grants such authorization for each		
36	prescription.		



.

(B)(i)(C)(i) Before dispensing, the pharmacist shall discuss verbally any suggested substitution with the patient and inform the patient that the patient has a right to refuse the substitution. (ii) The discussion under subdivision (17)(B)(i) (17)(C)(i) of this section shall include without limitation: (a) Notification to the patient that the therapeutically equivalent drug does not contain the identical active ingredient present in the prescribe prescribed drug; and (b) All differences in dosage and frequency between the prescribed drug and the therapeutically equivalent drug. (C) (D) The pharmacist shall send notice of the substitution to the prescriber in writing or by electronic communication within twenty-four (24) hours after the drug is dispensed to the patient. (E) Subdivision (17)(C) of this section does not apply to specific acts of drug therapy management or disease state management delegated to a pharmacist based upon a written protocol or patient care plan approved by a physician under § 17-92-101(16)(A)(ix);